| Literature DB >> 32448899 |
Massimo Vecchiato1, Antonio Martino1, Massimo Sponza2, Alessandro Uzzau1, Antonio Ziccarelli1, Federico Marchesi3, Roberto Petri1.
Abstract
Chylothorax is a serious complication of transthoracic esophagectomy. Intraoperative thoracic duct (TD) identification represents a possible tool for preventing or repairing its lesions, and it is most of the time difficult, even during high-definition thoracoscopy. The aim of the study is to demonstrate the feasibility of using near-infrared fluorescence-guided thoracoscopy to identify TD anatomy and check its intraoperative lesions during minimally invasive esophagectomy. A 0.5 mg/kg solution of indocyanine green (ICG) was injected percutaneously in the inguinal nodes of 19 patients undergoing minimally invasive esophagectomy in a prone position, before thoracoscopy. TD anatomy and potential intraoperative lesions were checked with the KARL STORZ OPAL1® Technology. In all of the 19 patients where transthoracic esophagectomy was feasible, the TD was clearly identified after a mean of 52.7 minutes from injection time. The TD was cut for oncological radicality in two patients, and it was successfully ligated under the ICG guide. No postoperative chylothorax or adverse reactions from the ICG injection occurred. The TD identification with indocyanine green fluorescence during minimally invasive esophagectomy is a simple, effective, and non-time-demanding tool; it may become a standard procedure to prevent postoperative chylothorax.Entities:
Keywords: esophagectomy; indocyanine green; prone position; thoracic duct; thoracoscopy
Mesh:
Substances:
Year: 2020 PMID: 32448899 PMCID: PMC7720005 DOI: 10.1093/dote/doaa030
Source DB: PubMed Journal: Dis Esophagus ISSN: 1120-8694 Impact factor: 3.429
Fig. 1Bilateral injection of the ICG in the inguinal nodes with an ultrasound guide.
Demographics and clinical data of patients
| Patient | Age | Sex | Site of tumor | Histotype | Approach | Neoadjuvant therapy | Injection site | 0.5 mg/kg | Time procedure | Time from injection and visualization (minutes) | Adverse reactions or iatrogenic lesions at the injection site | Section and ligation of the TD | Chylothorax |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 80 | F | Middle | Squamous | McKeown | Chemoradiotherapy | Foot and inguinal nodes | 22 | 15 | 60 | No | No | No |
| 2 | 70 | M | Lower | Adenocarcinoma | Ivor Lewis | Chemoradiotherapy | Inguinal nodes | 45 | 13 | 60 | No | No | No |
| 3 | 72 | M | Middle | Adenocarcinoma | Transhiatal | Chemoradiotherapy | Inguinal nodes | 37 | 10 | No | No | No | |
| 4 | 55 | M | Middle | Squamous | McKeown | Chemoradiotherapy | Inguinal nodes | 32 | 16 | 80 | No | Yes | No |
| 5 | 53 | M | Lower | Squamous | Ivor Lewis | Chemoradiotherapy | Inguinal nodes | 41 | 10 | 70 | No | No | No |
| 6 | 51 | F | Lower | Adenocarcinoma | Ivor Lewis | Chemoradiotherapy | Inguinal nodes | 27 | 7 | 55 | No | No | No |
| 7 | 69 | M | Middle | Squamous | NA | Chemoradiotherapy | Inguinal nodes | 29 | 11 | 41 | No | No | No |
| 8 | 74 | M | Lower | Squamous | McKeown | Chemoradiotherapy | Inguinal nodes | 29 | 8 | 46 | No | No | No |
| 9 | 59 | M | Lower | Adenocarcinoma | Ivor Lewis | Chemoradiotherapy | Inguinal nodes | 30 | 10 | 55 | No | No | No |
| 10 | 67 | M | Middle | Squamous | McKeown | Chemoradiotherapy | Inguinal nodes | 29 | 15 | 60 | No | No | No |
| 11 | 67 | M | Middle | Squamous | McKeown | Chemoradiotherapy | Inguinal nodes | 34 | 9 | 45 | No | Yes | No |
| 12 | 64 | M | Lower | Adenocarcinoma | Ivor Lewis | Chemoradiotherapy | Inguinal nodes | 42 | 7 | 50 | No | No | No |
| 13 | 78 | F | Superior | Squamous | McKeown | Chemoradiotherapy | Inguinal nodes | 30 | 10 | 50 | No | No | No |
| 14 | 81 | M | Middle | Squamous | McKeown | Chemoradiotherapy | Inguinal nodes | 36 | 8 | 50 | No | No | No |
| 15 | 69 | M | Lower | Adenocarcinoma | Ivor Lewis | Chemoradiotherapy | Inguinal nodes | 44 | 8 | 40 | No | No | No |
| 16 | 54 | M | Middle | Squamous | McKeown | Chemoradiotherapy | Inguinal nodes | 35 | 12 | 60 | No | No | No |
| 17 | 75 | F | Middle | Squamous | McKeown | Chemoradiotherapy | Inguinal nodes | 37 | 9 | 55 | No | No | No |
| 18 | 78 | M | Lower | Adenocarcinoma | Ivor Lewis | Chemoradiotherapy | Inguinal nodes | 40 | 9 | 45 | No | No | No |
| 19 | 81 | M | Lower | Adenocarcinoma | Ivor Lewis | Chemoradiotherapy | Inguinal nodes | 38 | 10 | 45 | No | No | No |
| 20 | 59 | M | Lower | Squamous | McKeown | Chemoradiotherapy | Inguinal nodes | 22 | 12 | 45 | No | Yes | No |
Fig. 22bis Identification of TD after the injection (NIR/ICG with SPECTRA A).
Fig. 3Identification of tributary and aberrant duct of TD (NIR/ICG with SPECTRA A).